What does Cellectis do?
What does Cellectis do?
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells.
What is UCART123?
Our wholly controlled product candidate, UCART123, is a gene-edited T-cell investigational drug that targets CD123, an antigen expressed at the surface of leukemic cells in acute myeloid leukemia (AML).
Who owns Cellectis?
Cytovia Therapeutics, Inc.
CAMBRIDGE, MA and NEW YORK, NY, February 16th 2021 – Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS – …
Where is cellectis based?
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, France, New York, New York and Raleigh, North Carolina.
Is cellectis a buy?
Cellectis has received a consensus rating of Buy. The company’s average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
How many employees does cellectis have?
Company Growth (employees)
| Employees (est.) (Jul 2021) | 272 | |
|---|---|---|
| Website Visits (Apr 2021) | 10.6 k | |
| Revenue (FY, 2017) | $33.7 M | (-40%) |
| Share Price (Aug 2021) | €12.3 | (+6%) |
| Cybersecurity rating | D | More |
Is edit stock a buy?
Editas Medicine has received a consensus rating of Hold. The company’s average rating score is 2.21, and is based on 7 buy ratings, 3 hold ratings, and 4 sell ratings.
Is edit a buy Zacks?
– EDIT – Stock Price Today – Zacks….(Delayed Data from NSDQ)
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 25.60% |
| 2 | Buy | 19.21% |
| 3 | Hold | 10.85% |
| 4 | Sell | 6.62% |
How did Cellectis make the UCARTCS1 car?
UCARTCS1 is based on a tailored manufacturing process developed by Cellectis, which removes both the CS1 antigen and TCR from the T-cell surface using TALEN® gene editing technology, before adding the CS1 CAR construct.
When was the Cellectis CAR T trial put on hold?
The FDA placed a clinical trial of another Cellectis’ CAR-T, UCART123, on hold in 2017 after a patient died, but cleared it to resume months later.
Why was ucartcs1a put on clinical hold?
The FDA has put a phase 1 trial of Cellectis’ off-the-shelf CAR-T therapy UCARTCS1A on clinical hold after learning of a death in the study. Cellectis said the multiple myeloma patient suffered a cardiac arrest after receiving the highest dose of the anti-CS1 allogeneic CAR-T.
Who is Cellectis and what do they do?
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART).